<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 04, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00001111</url>
  </required_header>
  <id_info>
    <org_study_id>REP0210</org_study_id>
    <nct_id>NCT00001111</nct_id>
  </id_info>
  <brief_title>Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer</brief_title>  
  <sponsors>
    <lead_sponsor>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sarcoma Alliance for Research through Collaboration (SARC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Threshold Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is
      safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft
      Tissue Sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TH-302 is designed to target the hypoxic regions of tumors which are generally located
      distant from tumor vessels.  Doxorubicin has poor tissue penetration and targets the regions
      of tumors that are located in proximity to the tumor vessels. The presence of hypoxia in
      solid tumors is associated with a more malignant phenotype and resistance to chemotherapy.
      The hypoxia-activated prodrug, TH-302, is designed to selectively target the hypoxic
      microenvironment.  Soft tissue sarcomas have evidence supporting the presence of hypoxia
      based on pO2 histography, F-MISO and gene expression profiling.  There is an absence of
      therapeutic options for subjects with soft tissue sarcoma.  Combining doxorubicin with
      TH-302 may enable the targeting of both the normoxic and hypoxic regions of soft tissue
      sarcoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of TH-302 in combination with doxorubicin</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy will be determined by overall survival in subjects with locally advanced unresectable or metastatic soft tissue sarcoma previously untreated with chemotherapy compared with doxorubicin alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue sarcoma compared with doxorubicin alone</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To investigate the pharmacokinetics of TH-302, Br-IPM, doxorubicin, and doxorubicinol in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>TH-302 in Combination with Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 in Combination with Doxorubicin</intervention_name>
    <description>300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.
Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.
Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.
Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.
Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302.</description>
    <arm_group_label>TH-302 in Combination with Doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.
Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.
Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.</description>
    <arm_group_label>Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 15 years of age

          -  Ability to understand the purposes and risks of the study and has signed or, if
             appropriate, the subject's parent or legal guardian has signed a written informed
             consent form approved by the investigator's IRB/Ethics Committee

          -  Pathologically confirmed diagnosis of soft tissue sarcoma of the following
             histopathologic types:

               -  Synovial sarcoma

               -  High grade fibrosarcoma

               -  Undifferentiated sarcoma; sarcoma not otherwise specified (NOS)

               -  Liposarcoma

               -  Leiomyosarcoma (excluding GIST)

               -  Angiosarcoma (excluding Kaposi's sarcoma)

               -  Malignant peripheral nerve sheath tumor

               -  Pleomorphic Rhabdomyosarcoma

               -  Myxofibrosarcoma

               -  Epithelioid sarcoma

               -  Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (MFH)
                  (including pleomorphic, giant cell, myxoid and inflammatory forms)

          -  Locally advanced unresectable or metastatic disease with no standard curative therapy
             available and for whom treatment with single agent doxorubicin is considered
             appropriate.

          -  Recovered from reversible toxicities of prior therapy

          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy of at least 3 months

          -  Acceptable liver, renal, hematological and cardiac function

          -  All women of childbearing potential must have a negative serum pregnancy test and all
             subjects must agree to use effective means of contraception

        Exclusion Criteria:

          -  Prior systemic therapy for advanced or metastatic disease (neoadjuvant therapy
             followed by surgical resection and adjuvant therapy permitted)

          -  Low grade tumors according to standard grading systems

          -  Prior therapy with ifosfamide or cyclophosphamide or other nitrogen mustards

          -  Prior therapy with an anthracycline or anthracenedione

          -  Prior mediastinal/cardiac radiotherapy

          -  Current use of drugs with known cardiotoxicity or known interactions with doxorubicin

          -  Anti-cancer treatment with radiation therapy, neoadjuvant or adjuvant chemotherapy,
             targeted therapies, immunotherapy, hormones or other antitumor therapies  within 4
             weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C)

          -  Significant cardiac dysfunction precluding treatment with doxorubicin

          -  Seizure disorders requiring anticonvulsant therapy unless seizure-free for the last
             year

          -  Known brain metastases (unless previously treated and well controlled for a period of
             ≥ 3 months)

          -  Previously treated malignancies, except for adequately treated non-melanoma skin
             cancer, in situ cancer, or other cancer from which the subject has been disease-free
             for at least 5 years

          -  Severe chronic obstructive or other pulmonary disease with hypoxemia or in the
             opinion of the investigator any physiological state likely to cause normal tissue
             hypoxia

          -  Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without
             complete recovery

          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy

          -  Prior therapy with a hypoxic cytotoxin

          -  Subjects who participated in an investigational drug or device study within 28 days
             prior to study entry

          -  Known infection with HIV, hepatitis B, or hepatitis C

          -  Subjects who have exhibited allergic reactions to a structural compound similar to
             TH-302,doxorubicin or their excipients

          -  Females who are pregnant or breast-feeding

          -  Concomitant disease or condition that could interfere with the conduct of the study,
             or that would, in the opinion of the investigator, pose an unacceptable risk to the
             subject in this study

          -  Unwillingness or inability to comply with the study protocol for any reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Tap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlo Beasley</last_name>
      <phone>480-301-6492</phone>
      <email>beasley.marlo@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly Curtis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Jordan</last_name>
      <phone>520-694-9056</phone>
      <email>sdeporter@azcc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Lee Cranmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC-Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Massopust</last_name>
      <phone>323-865-0089</phone>
      <email>massopust_K@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>James Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaMarr Taylor Smith</last_name>
      <phone>310-794-8929</phone>
      <email>LaMarrTaylor@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Noah Federman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Chua</last_name>
      <phone>310-552-9999</phone>
      <email>vchua@sarcomaoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sant P Chawla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Comprehensive Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ahern</last_name>
      <phone>650-725-6413</phone>
      <email>mahern@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen Ganjoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Mathew</last_name>
      <phone>202-877-5371</phone>
      <email>Christopher.T.Mathew@Medstar.net</email>
    </contact>
    <investigator>
      <last_name>Dennis Priebat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Center for Gynecologic Oncology</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Thompson</last_name>
      <phone>954-406-1360</phone>
      <email>lthompson@crninc.org</email>
    </contact>
    <investigator>
      <last_name>Fernando Recio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Florida-Cancer Clinical Studies Unit</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Guadalupe</last_name>
      <phone>904-953-6175</phone>
      <email>guadalupe.salvador@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Attia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sierra Theodore</last_name>
      <phone>813-745-3620</phone>
      <email>sierra.theodore@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Damon Reed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University, Midtown Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stepanie McMillan</last_name>
      <phone>404-686-1855</phone>
      <email>sjmcmil@emory.edu</email>
    </contact>
    <investigator>
      <last_name>William Read, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Moore</last_name>
      <phone>770-496-9427</phone>
      <email>Christopher.Moore@gacancer.com</email>
    </contact>
    <investigator>
      <last_name>Gina D'Amato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kootenai Health - Kootenai Cancer Center</name>
      <address>
        <city>Coeur d`Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Golden</last_name>
      <phone>208-619-4151</phone>
      <email>sgolden@kmc.org</email>
    </contact>
    <investigator>
      <last_name>Brian Samuels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Collins</last_name>
      <phone>312-695-1335</phone>
      <email>catherine-collins@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Agulnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talal Ali</last_name>
      <phone>312-942-1237</phone>
      <email>Talal_Ali@Rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ali</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marta Batus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Edwards</last_name>
      <phone>847-410-0662</phone>
      <email>sedwards@oncmed.net</email>
    </contact>
    <investigator>
      <last_name>Pamela Kaiser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Potter, MS</last_name>
      <phone>317-278-6616</phone>
      <email>krpotter@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Rushing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Care - University of Iowa Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Swift</last_name>
      <phone>319-353-8699</phone>
      <email>judy-swift@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammed Milhem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret F Ferreira, MS,RN</last_name>
      <phone>410-955-7349</phone>
      <email>mfogle1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Christian Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute Center for Sarcoma and Bone Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley O'Meara</last_name>
      <phone>617-643-5411</phone>
      <email>ALOMEARA@Partners.org</email>
    </contact>
    <investigator>
      <last_name>David D'Adamo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geno Metko</last_name>
      <phone>734-647-2095</phone>
      <email>ginom@med.ucmich.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Schuetze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Olsen</last_name>
      <phone>507-266-3477</phone>
      <email>olsen.laurnice@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Okuno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Bearden</last_name>
      <phone>314-362-0208</phone>
      <email>lbearden@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Van Tine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Carrillo</last_name>
      <phone>718-405-8505</phone>
      <email>TCARRILL@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Petra Rietschel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Hicks</last_name>
      <phone>716-845-8947</phone>
      <email>Karen.Hicks@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Nikhil Khushalani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cate Hirst</last_name>
      <phone>646-888-4374</phone>
      <email>hirstc@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>William Tap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Wilfred</last_name>
      <phone>212-305-6837</phone>
      <email>sw2713@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Kalinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Hematology-oncology Associates-Blumenthal Cancer Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Gruntz, RN,BSN</last_name>
      <phone>704-446-1921</phone>
      <email>allison.gruntz@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Livingston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Duffy</last_name>
      <phone>919-668-3726</phone>
      <email>eileen.duffy@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Riedel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Black</last_name>
      <phone>336-716-9342</phone>
      <email>jhblack@wfubmc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Savage, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Terry, MD</last_name>
      <phone>216-444-9302</phone>
      <email>terrym@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Budd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Arthur G. James Cancer Hospital and Richard J Solove Research Institue, The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvinder Bhinder, MD</last_name>
      <phone>614-293-2886</phone>
      <email>Arvinder.Bhinder@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Arvinder Bhinder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology Hematology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Ripley-Weeks</last_name>
      <phone>215-829-6489</phone>
      <email>dawnripley-weeks@pennoncology.com</email>
    </contact>
    <investigator>
      <last_name>Arthur Staddon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Berry</last_name>
      <phone>215-728-5623</phone>
      <email>Alison.Berry@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Margaret VonMehren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg Medical Center</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Mader</last_name>
      <phone>412-235-1149</phone>
      <email>madersa@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hussein Tawbi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUSC - Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Salamacha</last_name>
      <phone>843-792-7030</phone>
      <email>salamach@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Kraft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tayna Davis</last_name>
      <phone>615-875-1188</phone>
      <email>Tayna.e.davis@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Vicki Keedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Lepuschenko</last_name>
      <phone>802-656-9924</phone>
      <email>karen.lepuschenko@uvm.edu</email>
    </contact>
    <investigator>
      <last_name>Claire Verschraegen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth Universtiy-Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Halverson, RN</last_name>
      <phone>804-628-1888</phone>
      <email>mmhalverson@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Poklepovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Gaeler</last_name>
      <phone>206-288-7518</phone>
      <email>cgaeler@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Robin Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginny Katzke</last_name>
      <phone>414-805-0599</phone>
      <email>vkatzke@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Matt Lasowski</last_name>
      <phone>14148058375</phone>
      <email>mlasowski@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Charlson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ. Klinik fur Innere Medizin I Internistische Onkologie Medizinische Universitat Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Plangger</last_name>
      <phone>435125042333</phone>
      <email>sarah.plangger@uki.at</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Eisterer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marika Rosner</last_name>
      <phone>431404004689</phone>
      <email>marika.rosner@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Thomas Brodowicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences - Department of Medicine</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <zip>T2N4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institue</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BCCA- Vancouver Cancer Centre - Division of Medical Oncology</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3E0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Herlev at Copenhagen</name>
      <address>
        <city>Herlev</city>
        <state>Copenhagen</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO Rene Gauducheau</name>
      <address>
        <city>Saint Herblain Cedex</city>
        <state>Nantes</state>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Departement d'Oncologie Medicale</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Département d'Oncologie Moléculaire, Institut Paoli-Calmettes (IPC) and U119 Inserm</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow, Department of Hematology, Oncology, and Palliative Care, Sarcoma Center Berlin-Brandenburg</name>
      <address>
        <city>Berlin</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH) - Klinik fuer Haemonstaseologie, Onkologie und Stammzelltransplantation</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Div. of Surgical Oncology &amp; Thoracic Surgery, Mannheim University Medical Center</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68165</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Munchen-Grosshadern, Medizinische Klinik un Poliklinik lll</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kufer</last_name>
      <phone>+498970956157</phone>
      <email>Andrea.Kufer@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Beatrice Stockheim</last_name>
      <phone>+498970956157</phone>
      <email>Beatrice.stockheim@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Marcus Schlemmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilhelm's University, Universitatsklinikum Muenster, Medizinische Klinik und Poliklinik A, Albert-Schweitzer-Campus 1</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Honvedkorhaz, Onkologiai Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>H-1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Megyei Onkologiai Kozpont</name>
      <address>
        <city>Szolnok</city>
        <zip>H-5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sharette Institute of Oncology, Hadassah-Hebrew University Medical Center, Hadassah Medical Org-Ein Karem</name>
      <address>
        <city>Kiryat Hadassah</city>
        <state>Jerusalem</state>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di Riferimento Oncologico-Struttura Operativa</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia, Instituto per la Ricerca e la Cura del cancro (I.R.C.C.), Dipartimento Oncologico, Direzione Operativa Oncologia Medica a Direzione Universitaria</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico (CRO)</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Garibaldi</name>
      <address>
        <city>Catania</city>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS-Instituo Nazionale Tumori Fondazione G Pascale Diparti</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria-Policlinico Paolo Giacco</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS - IFO - Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASL TO/2 di TORINO_Presidio Sanitario Gradenigo, S.C. di Oncologia</name>
      <address>
        <city>Torino</city>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzkie Centrum Onkologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im M. Sklodowskiej-Curie</name>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>GUZ &quot;Regional Oncology Dispensay&quot;, Irkutsk</name>
      <address>
        <city>Irkutsk</city>
        <zip>644035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Ponomarenko</last_name>
      <phone>7395295551</phone>
      <email>ponomarenkodm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Viktoria Dvornichenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GUZ &quot;Regional Oncology Dispensay&quot;, Kazan</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yana Shagieva</last_name>
      <phone>7435257346</phone>
    </contact>
    <investigator>
      <last_name>Guzel Mukhamedshina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FGU Moscow Research Institute of Oncology named after P.A. Hertzen of Rosmedtechnology</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Yakovleva</last_name>
      <phone>784959450320</phone>
      <email>dryakovleva@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Valery Teplyakov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ROTSN RAMS them. Н.Н.Блохина NN Blokhin</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>H.U. Canarias, Hospital Universitario de Canarias. Servicio de Oncología Médica</name>
      <address>
        <city>Tenerife</city>
        <state>Canarias</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu, Department de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Llanos</last_name>
      <phone>34932804000</phone>
      <phone_ext>2361</phone_ext>
      <email>cllanosp@hsjdbcn.org</email>
    </contact>
    <investigator>
      <last_name>Jaume Mora Graupera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romina Ribas Carbonell</last_name>
      <phone>+34935537118</phone>
    </contact>
    <investigator>
      <last_name>Antonia Lopez Pousa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Feliu</last_name>
      <phone>+34932607822</phone>
      <email>cfeliu@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Xavier Garcia del Muro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal.</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Lavin</last_name>
      <phone>+34913368263</phone>
      <email>slavin.hrc@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Pilar Domingo Garcia</last_name>
      <phone>+34913368263</phone>
      <email>mariapilar.domingo@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Angeles Vaz Salgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad Complutense Madrid Facultad de Medicina - Hospital Universitario 12 de Octubre, Servicio de Oncologia Medica Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 3, 2013</lastchanged_date>
  <firstreceived_date>September 20, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TH-302</keyword>
  <keyword>TH-CR-406</keyword>
  <keyword>SARC021</keyword>
  <keyword>Locally Advanced Soft Tissue Sarcoma</keyword>
  <keyword>Metastatic Soft Tissue Sarcoma</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Doxorubicin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
